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ABSTRACT 27 
Genetic and epigenetic profile changes associated with individual radiation sensitivity are well 28 
documented and have led to an increase in our understanding of the mechanisms of the 29 
radiation-induced DNA damage response. However, the quest to identify reliable biomarkers 30 
of individual radiation sensitivity is on-going. Herein, we report a multi-biomarker approach 31 
using traditional cytogenetic biomarkers, DNA damage biomarkers and transcriptional 32 
microRNA (miR) biomarkers coupled with their potential gene targets to identify 33 
radiosensitivity in ATM (Ataxia-Telangectasia Mutated)-deficient lymphoblastoid cell lines 34 
(LCL) and  ATM proficient cell lines that were used as controls.  35 
Cells were irradiated with 0.05 Gy and 0.5 Gy using an Elekta Precise linac, with sham-36 
irradiated cells as controls. At 1 hour post irradiation, cells were fixed for γH2AX analysis as a 37 
measurement of DNA damage, and cytogenetic analysis using the G2 chromosomal sensitivity 38 
assay, G-Banding and FISH techniques. RNA was also isolated for genetic profiling by 39 
microRNA (miR) and RT-PCR analysis. A panel of 752 miR were analysed, and potential target 40 
genes phosphatase and tensin homolog (PTEN) and cyclin D1 (CCND1) measured. 41 
The cytogenetic assays revealed that although the control cell line had functional cell cycle 42 
checkpoints, the radiosensitivity of the control and AT cell lines were similar. Analysis of DNA 43 
damage in all cell lines, including an additional control cell line, showed elevated γH2AX levels 44 
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for only one A-T cell line. Of the 752 miR panel analysed, 8 miR were found to be up-regulated, 45 
with 6 miR down-regulated in the AT cells compared to the control. Up-regulated miR-152-46 
3p, miR-24-5p and miR-92-15p and all down-regulated miR were indicated as modulators of 47 
PTEN and CCDN1. Further measurement of both genes validated their potential role as 48 
radiation response biomarkers. The multi-biomarker approach not only revealed potential 49 
candidates for radiation response but also additional mechanistic insights of response in AT 50 
deficient cells. 51 
 52 
INTRODUCTION 53 
In the last decade, the definition and classification of ionizing radiation biomarkers have been 54 
reported through several European Union Framework 7 multidisciplinary consortia such as 55 
Multibiodose (2010-2013), RENEB (Realizing the European Network in Biodosimetry (2012-56 
2015)) and DoReMi (Low dose Research towards multidisciplinary Integration (2010-2015)) 57 
with the multipurpose use of biomarkers for epidemiological and biodosimetry investigations 58 
(1-4). These include biomarkers of low dose exposure and biological response, individual 59 
susceptibility and early detection of a radiation-induced health effect, of which considerations 60 
to the characteristics of a good biomarker and the useful in vitro approaches have been made. 61 
Although the DoReMi project was completed in 2015, research has continued under Melodi 62 
(Multidisciplinary European Low Dose Initiative (5)) and the DoReMi  multidisciplinary report 63 
(4) was later updated to include novel radiation biomarkers emerging from technical 64 
advances in metabolomics and transcriptomics, and to critique the current status of 65 
biomarkers (6). A roadmap for the development of biomarkers from discovery to 66 
implementation was presented for biomarkers of low dose exposure and early or late 67 
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radiation effects.  The authors highlighted that the majority of potential biomarkers are in the 68 
development stage with only one biomarker that has progressed to the final stages of 69 
development with IR specific mRNA transcript profiles for FDXR. This gene has been reported 70 
in many proposed gene signature panels due to dose-dependent induction in different cell 71 
and tissue types (7-10). Furthermore, inter-comparison laboratory or biodosimetry studies 72 
have demonstrated that both single genes and gene panels can be used to estimate exposure 73 
of samples with the same accuracy and sensitivity of established and traditional cytogenetic 74 
assays (11-12). 75 
The DNA damage response (DDR) pathways are potential targets for transcriptional 76 
biomarkers of cancer susceptibility and radiation exposure; in particular the ATM/chk2/p53 77 
pathway, which responds to radiation-induced double strand breaks (DSB) leading to cell 78 
cycle arrest or DNA repair. The DSB are sensed by the MRN complex (MRE11- Rad50- NBS-1) 79 
leading to ATM activation, phosphorylation of serine 139 of γH2AX and extension around the 80 
DSB, initiating repair protein assembly (13-14). Consequently, γH2AX has been used as a 81 
biomarker of DNA damage and repair and for predicting radiosensitivity in individuals (15-17) 82 
and applied to a wide range of established cell lines, primary cell cultures  and peripheral 83 
blood lymphocytes as well as 2-dimensional tissue models and tissue sections as reviewed by 84 
Rothkamm et al (18). The role of ATM, a PI3K-like kinase that is phosphorylated at specific 85 
serine/threonine sites when activated, is central to this pathway. Deficiencies in the ATM 86 
gene lead to phenotypic elevated radiosensitivity observed in clinical conditions such as 87 
Ataxia Telangiectasia (AT) and AT-like disorders (ATLD) (19-21).  After DSB are sensed, the cell 88 
cycle must be halted to allow sufficient time for DNA repair processes, facilitated through 89 
ATM- activated Chk2. This leads to p53- mediated inhibition of cyclins and cyclin-dependent 90 
kinases, such as Cyclin D1 (CCDN1) and CDK4/6 at the G1 cell cycle checkpoint (22). Failure to 91 
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undergo DNA repair may result in permanent cell cycle arrest, enhanced apoptosis or cellular 92 
senescence. The PI3K/Akt pathway is also involved in the survival of cells after IR-induced DNA 93 
damage, through overriding the G2/M cell cycle arrest mechanism; conversely inhibition of 94 
PI3K or Akt, for example through the tumour suppressor PTEN, induces cell apoptosis and 95 
therefore elevates cellular radiosensitivity (23-25).   96 
Further transcriptomic analyses have shown that microRNA (miR) are promising biomarkers 97 
of radiation oncology (26). They are small, non-coding RNA molecules of 19-22 nucleotides 98 
that regulate more than 50% of cell protein coding genes and regulate important processes 99 
of the DNA damage response such as DNA repair, cell cycle control and apoptosis.  It has 100 
previously been shown that important genes of these processes (such as CDKN1, SESN1, ATF3, 101 
MDM2, PUMA and GADD45A) were upregulated in stimulated T cells in response to IR with a 102 
significant dose- and time-dependent modification of miR expression (specifically miR-34-5p 103 
and miR-182-5p) (27-28).  104 
Given the current published evidence associating the ATM/Chk2/P53 pathway with elevated 105 
radiosensitivity and potentially regulated by miR, normal and AT radiosensitive 106 
lymphoblastoid cell lines were used to measure IR-induced DNA damage using the classic 107 
cytogenetic and DNA damage biomarkers followed by miR screening and identification of 108 
gene targets in a multi-biomarker approach. All biomarkers selected for this study were based 109 
on the DoReMi (Low dose Research towards multidisciplinary Integration) multidisciplinary 110 
biomarker reports by Pernot et al (4), and Hall et al (6), and the recent report which reviews 111 
the progress made in low dose health risk research by the DoReMi consortium (29).  112 
 113 
MATERIALS AND METHODS 114 
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Cell Lines and culture conditions 115 
Epstein-Barr immortalised lymphoblastoid cell lines (LCLs) coded; C1, 2139, AT2Bi and AT3Bi 116 
were used for this study.  C1 and 2139 cell lines were derived from healthy donors and kindly 117 
gifted by the Queensland Institute of Medical Research, Australia and the Institut Curie, Paris, 118 
respectively. The AT2Bi and AT3Bi cell lines were derived from clinically established Ataxia-119 
Telangectasia patients and kindly gifted from the College of Medical and Dental Sciences, 120 
University of Birmingham, UK.  Both AT2Bi and AT3Bi are known to have defective Ataxia 121 
Telangiectasia- mutated (ATM) protein causing the typical clinical and cellular manifestations 122 
of AT including heightened radiosensitivity (30). C1, 2139, AT2Bi and AT3Bi lymphoblast cells 123 
were cultured in RPMI 1640 medium (Sigma Aldrich, Wexford, Ireland) supplemented with 124 
12.5% FBS and 1% L-Glutamine (Sigma Aldrich), at 37 °C and 5 % CO2.  All cell lines were seeded 125 
at a density of 2x105/ml and passaged once a density of 1x106/ml cells had been reached.  126 
Cells were seeded 18 hours prior to irradiation, a T25 flasks at a density of 1x106cells/ml (G2 127 
chromosomal radiosensitivity assay), 2x104 cells in total (growth curves), or 2x105/ml (γH2AX 128 
and molecular experiments) at a final volume of 5 ml per T25 flask (Sarstedt, Numbrecht, 129 
Germany). 130 
Irradiation Conditions 131 
Cells were irradiated using a 6MV photon beam produced by an Elekta Precise linear 132 
accelerator (LINAC) at St. Luke’s Hospital, Dublin, operating at a nominal dose rate of 133 
6Gy/min. The LINAC was calibrated in accordance with the 1990 IPSM code of practice by the 134 
Medical Physics Department at St. Luke’s Hospital (31), with 100 Monitor Units (MU, a 135 
measure of ‘beam on’ time) delivered a dose of 1Gy at 1.4 cm deep in water positioned 100 136 
cm from the source for a 10 X 10 cm2 field. To achieve a uniform irradiation of flasks, the 137 
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irradiation conditions were altered from those at calibration. A 30 x 35 cm2 field was used to 138 
deliver each dose. The flasks were also positioned 10 cm deep in a water equivalent phantom 139 
90 cm from the source in which 100MU delivers a dose of 0.812Gy at 10 cm deep in water for 140 
a 10 x 10 cm2 field. The number of MU required to deliver each of the doses outlined were 141 
corrected for the different scatter conditions present with the larger field size (30 x 35 cm2). 142 
Therefore, a correction factor of 1.1372 was applied, which is the ratio of the field area of a 143 
large field to a smaller one. Thus, at 90 cm from the source, 100MU delivers a dose of 0.9234 144 
Gy (0.812 X 1.1372), and therefore the delivery of 0.05Gy required 6 MU and 0.5Gy required 145 
55 MU (MU were rounded up to the nearest whole number as partial MU could not be 146 
delivered on the LINAC). The calculated doses were verified using Gafchromic EBT3 film 147 
(Ashland Inc., Bridgewater, NJ, USA) and the film was calibrated against a Farmer type 148 
ionization chamber using the triple channel dosimetry method (31). The film was scanned 149 
using the single scan protocol (32) on an Epsont Expression 10000 XL scanner with the 150 
recommended scanning resolution of 72 dpi in a 48-bit RGB format (31, 33-34). Glass was 151 
placed over the calibration and test film during scanning to minimize ringing artifacts. The film 152 
was analyzed using FilmQA Pro (Ashland Inc., Bridgewater, NJ, USA). 153 
Cell Growth Assay 154 
To determine the effect of radiation on the growth potential of the cells, flasks were seeded 155 
and irradiated as described above. At 5-7 days post- irradiation, cells were isolated and 156 
counted in duplicate using a Coulter cell counter (Beckman Coulter, Co Clare, Ireland). Total 157 





Gamma-H2AX analysis by Flow Cytometry 161 
DNA damage was determined by γ-H2AX analysis and measured by flow cytometry.  Cells 162 
were fixed at 1-hour post irradiation in 2 % paraformaldehyde and stored in 70 % ethanol at 163 
-20 °C.  To stain, cells were permeabilised using 0.25 % Triton X, followed by blocking with a 164 
4 % FBS solution in PBS for 30 minutes.  A primary antibody solution (anti-phospho-histone 165 
H2A.X (Ser139), clone JBW301, 1:500; Merck Millipore, Darmstadt, Germany) was added and 166 
incubated overnight at 4 °C, followed by a 1-hour incubation with the secondary antibody 167 
(F(ab’)- Goat anti-Mouse IgG (H+L), Alexa Fluor-488, 1:200; Thermo Fisher, Carlsbad, CA, USA) 168 
at room temperature.  Cells were washed, counterstained with 1 % propidium iodide solution 169 
and analysed on an Accuri C6 flow cytometer (BD, Oxford, UK).  The mean fluorescence of 170 
10,000 cells was calculated using the Accuri C6 Sampler software, with cells stained only with 171 
the secondary antibody acting as a negative control for each sample. 172 
G2 chromosomal radiosensitivity assay 173 
The G2 Chromosomal radiosensitivity assay as previously reported for whole blood 174 
lymphocytes (35-37), was applied to all 2139, AT2Bi and AT3Bi cells to measure radiation-175 
induced cell cycle checkpoint response by mitotic indices and G2 chromosomal 176 
radiosensitivity. The mitotic index (MI) was calculated by counting the ratio of cells in 177 
metaphase to all cells on the slide up to 1000 cells in total for each dose (0 Gy and 0.5 Gy) and 178 
cell line. Radiation-induced mitotic inhibition (RIMI) was calculated by subtracting the 0.5 Gy 179 
MI from the 0 Gy MI. A G2 radiosensitivity score was assigned to each of the cell lines and 180 
irradiation dose by calculating the total number of chromosomal aberrations per 100 181 
metaphases scored for each cell line and dose. A radiation-induced G2 score (RIG2) was 182 
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calculated by subtracting the spontaneous aberrations in the G2 score at 0 Gy from those 183 
recorded at 0.5 Gy. 184 
Cytogenetic G-Banding and karyotyping 185 
Cytogenetic preparations were made from irradiated 2139 and AT (AT2Bi and AT3Bi) LCL 186 
according to the G2 chromosomal radiosensitivity assay. For G-Banding, the metaphase 187 
spreads on glass slides were covered with 30% hydrogen peroxide solution for one minute 188 
followed by a wash with 0.9% NaCl solution. The metaphase preparations were then placed 189 
in trypsin solution for 2 mins, washed with Gurr buffer (pH 8) and then stained in 1 ml of 190 
Leishmann: Gurr buffer (1:2) solution for 1 min.  The slides were washed with Gurr buffer, 191 
then distilled water and dried before they were mounted with a coverslip using DPX. Each 192 
slide was evaluated under the microscope set up for bright-field use, noting conditions of 193 
under or over banding or staining. Twenty five metaphases were karyotyped under the 194 
microscope and analysed for chromosomal aberrations 195 
Fluorescent In Situ Hybridisation (FISH)  196 
Cytogenetic preparations (metaphase spreads as above) obtained from radiation- exposed  197 
2139, AT2Bi and AT3Bi LCL were soaked in sodium chloride and sodium citrate buffer (SCC) 198 
for 2mins at 37°C, before being applied to/ treated with protease solution for 30-40 seconds 199 
at 37°C. Slides were then washed in 1xPBS, dehydrated in an ethanol series (70%, 85% and 200 
100%) for 2 minutes each at RT and air dried before hybridisation. Hybridisation FISH probes 201 
were used to identify deletions or rearrangements in ATM-TP53 particularly for the AT cells 202 
(AT2Bi and AT3Bi). Probes for ATM-TP53 were used to confirm the presence of ATM or TP53 203 
gene in all LCL. Conditions such as B-cell chronic lymphocytic leukaemia (B-CLL), a malignancy 204 
often associated with Ataxia-Telangectasia has shown deletions in the genes of ATM (38, 39) 205 
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and P53 (40). Probes were mixed according to the manufacturer’s instructions and the 206 
required amount was added to each slide. Slides were transferred to a Hybrite machine with 207 
the selected Hybridisation program of 75°C for 2 min and 37°C for 20 hours. When hybridised 208 
samples were removed, the slides were immersed in wash solution (0.4xSSC/0.3% NP 40) for 209 
2 minutes and then transferred into a solution of 2xSSC/0.1% NP40 for a minimum of 1 210 
minute. DAPI (20μl) was added as a counterstain and slides were mounted in coverslips. For 211 
FISH microscopy, 100 Interphase cells were recorded.  212 
MicroRNA expression 213 
An expression panel of 752 miR was performed on 2139, AT2Bi and AT3Bi cell lines (Exiqon, 214 
Vedbaek, Denmark), in accordance with company protocols. Briefly, RNA (50ng) was reverse 215 
transcribed and cDNA assayed in 10µl PCR reactions (miRCURY LNA™ universal RT microRNA 216 
PCR, Polyadenylation and cDNA synthesis kit, ExiLENT SYBR® Green master mix).  The 217 
amplification was performed in a LightCycler® 480 Real Time PCR System (Roche) in 384 well 218 
plates. Melting curve and Cq values were analysed using Roche LC software. Cq values were 219 
calculated as the second derivative, with values greater than 37 omitted from further analysis. 220 
All data was normalized to the average of assays detected in all samples (average – assay Cq). 221 
Gene Expression 222 
Irradiated LCL were analysed for selected PTEN and CCDN1 gene expression by Real Time PCR 223 
(RT-PCR).  RNA was extracted from cells using the phenol-chloroform method and 224 
concentration measured using the Nanodrop (Maestrogen, Las Vegas, NV, USA).  CDNA was 225 
synthesised using the q-script cDNA kit (Quanta Bio, Beverly, MA, USA), according to 226 
manufacturer’s instructions.  Primers for Tubulin, PTEN and CCND1 were designed (Table 1) 227 
and synthesised (Sigma Aldrich), and reactions were performed in duplicate in 96 well plates 228 
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(Applied Biosystems, Carlsbad, CA, USA).  Each reaction was composed of 10 µl SYBR Green 229 
with low ROX, (Kapa Biosystems, London, UK), 1 µl of forward and reverse primers, 6 µl PCR 230 
grade water, and 2 µl cDNA.  Non template controls replaced cDNA with 2 µl PCR grade water. 231 
Reactions were run for 45 cycles on AB 7500 fast PCR cycler (Applied Biosystems). 232 
 233 
Table 1 Forward and reverse primer sequences for housekeeping gene Tubulin, and for 234 
targets PTEN and CCND1  235 
Gene  Forward Sequence Reverse Sequence 
Tubulin 5'GCTTCTTGGTTTTCCACAGC'3 3'CTCCAGCTTGGACTTCTTGC'5 
PTEN AGACAAATTCGGGCTATTCTGC ACCAGGTGCTTCATAGAGTAGG 
CCND1 GACAGGTCACATCAGAAAGAGC CCTTCAGAGTAATTTGCCCAGG 
 236 
 237 
Statistical Analysis  238 
All statistical analysis was performed using Microsoft Excel, versions 2010-2016. Mean and 239 
standard deviations were calculated, and significance was determined using paired or 240 
unpaired t-tests of each radiation dose relative to its 0 Gy control, for each individual cell line, 241 
as appropriate.  242 
 243 
RESULTS 244 
Cell Growth assay for monitoring cellular viability 245 
All cell lines were irradiated to 0.05 and 0.5 Gy and cultured for 5 days to measure growth 246 
potential. Percentage growth was calculated relative to the sham-irradiated control after 5 247 
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days in culture, and counted using a Coulter Counter and displayed in Figure 1(A).  After 5 248 
days in culture the control 2139 cells indicated a linear dose response for each low dose (0.05 249 
and 0.5Gy) compared to the 0Gy control (Figure 1A). Similarly the AT cells (AT2Bi and AT3Bi) 250 
indicated a dose response for 0.5Gy but not 0.05Gy. This was expected because we previously 251 
reported differential molecular mechanisms of Apoptosis for 0.05Gy compared to 0.5Gy 252 
between 1hr and 24hr direct irradiation (41). The additional control cell line C1 did not show 253 
a radiation dose response comparative to the 2139 control cells. 254 
 255 
γH2AX Biomarker of DNA damage response 256 
All cell lines were irradiated to 0.05 and 0.5 Gy and fixed for Gamma-H2AX (γH2AX) analysis 257 
through  flow cytometry as shown in Figure 1 (B). % positive cells were calculated, and 258 
normalised to the sham-irradiated control of each cell line. Since the cytogenetic biomarker 259 
of radiosensitivity (G2 chromosomal radiosensitivity) did not discriminate G2 radiosensitivity 260 
between the control 2139 and AT cells (AT2Bi and AT3Bi), the γH2AX assay was employed to 261 
measure double strand breaks (DSBs) induced by radiation in all cells. An additional control 262 
cell (C1) with functional ATM similar to 2139 was also analysed. Fluorescent foci are equal to 263 
the number of DSB induced by IR. Figure 1B presents γH2AX positive cells in the 4 LCLs at 1 264 
hour post-irradiation. A modest increase in γH2AX positive cells was evident in the AT3Bi cell 265 
line to 1.5 fold of the 0 Gy control, however this was not significant (p>0.05). Irradiation of 266 
the 2139 and AT2Bi cell line decreased γH2AX levels below that of the sham-irradiated cells, 267 
however this was not significant (p>0.1). There was no dose dependence of response in any 268 
cell line tested (Figure 1B). This assay was also performed at later timepoints with no 269 





Figure 1: Control (C1 and 2139) and AT (AT2Bi and AT3Bi) LCLs exposed to 0Gy, 0.05Gy and 273 
0.5Gy IR for measuring (A) Cell growth and (B) γH2AX as a biomarker for DNA double strand 274 
breaks induced by IR. Data shown are representative of 4 independent experiments, mean 275 
+/- SD 276 
Cytogenetic Biomarkers of radiation response 277 
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The G2 chromosomal radiosensitivity assay was used as cytogenetic biomarker of low-dose 278 
radiation-induced effects in the control 2139 and AT (AT2Bi and AT3Bi) lymphoblastoid cell 279 
lines. Assessment of mitotic indices (MI) through the G2 chromosomal radiosensitivity assay 280 
is a good indicator of cell cycle checkpoint response to ionising radiation, whereby radiation-281 
induced mitotic inhibition (RIMI) is the calculated difference between the 0.5 Gy and 0 Gy MI. 282 
The normal expected MI for the G2 chromosomal radiosensitivity varies between 2-5%, 283 
whereas the RIMI can be varied depending on cellular response to IR. All cell lines presented 284 
MI within the expected ranges for 0 Gy as presented in Figure 2A, however RIMI was more 285 
pronounced in 2139 (1.2) compared to AT2Bi (-0.3) and AT3Bi (0.6). This indicated that the 286 
control cells 2139 had superior cell cycle checkpoint efficacy compared to the AT cells, 287 
probably due to functional ATM. All cell lines presented elevated G2 chromosomal 288 
aberrations when irradiated to 0.5 Gy compared to their non-irradiated counterpart as 289 
presented in Figure 2B. Interestingly, the control 2139 cell line had similar radiation-induced 290 
G2 chromosomal radiosensitivity RIG2 (203 aberrations/100 metaphases) as the two AT cell 291 
lines AT2Bi and AT3Bi (134 and 183 aberrations/100 metaphases respectively), which 292 
indicated that although checkpoint response by MI appeared to be functional compared to 293 
the AT cells, radiation-induced chromosomal damage was similar to the AT cells.  This finding 294 
merited further cytogenetic investigation, performed in collaboration with the Genetics 295 
Department, Our Lady’s Children’s Hospital, Crumlin, Dublin. Cytogenetic karyotyping using 296 
the G-Banding Technique was performed on the 2139 and AT cells (AT2Bi and AT3Bi) and 297 
followed up with Fluorescent In-Situ Hybridisation (FISH) using an ATM/TP53 probe.  The 298 
cytogenetic analysis on 2139 cells surprisingly showed a loss of a sex chromosome in all of the 299 
cells analysed (Figure 3), with no other single cell or recurrent aberrations detected. The loss 300 
of a sex chromosome is associated with the constitutional diagnosis of Turners syndrome in 301 
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females. FISH analysis using ATM (11q22)/TP53 (17p13.1) probe set presented two copies of 302 
each ATM and P53 in each cell line with no detectable deletions, numerical aberrations or 303 
translocations at these loci in the 100 Interphase cells analysed. 304 
 305 
 306 
Figure 2: Control (2139) and AT (AT2Bi and AT3Bi) LCLs exposed to 0Gy (grey bars) and 0.5Gy 307 
(black bars) in G2 chromosomal radiosensitivity assay for (A) Mitotic Index and (B) G2 score. 308 






Figure 2: G-banding Karyotype report on 2139 and AT (AT2Bi and AT3Bi) LCLs reveal loss of 313 
sex chromosome X in 2139 cells (bottom left) and two copies of ATM and TP53 in all cells 314 
 315 
MicroRNA biomarkers of radiation response 316 
MicroRNA (miR) analysis was performed on the control (2139) and two AT (AT2Bi, AT3Bi) cell 317 
lines, to generate miR expression profiles and elucidate the efficacy of miR as a biomarker of 318 
radiation response, compared to the cytogenetic and DNA damage biomarkers shown in 319 
Figures 1-3. Figure 4A illustrates a heatmap presenting the most highly expressed miR in the 320 
cell profiles, which were then further analysed to determine their increase or decrease in cells 321 
deficient in ATM relative to the mean of all cell lines (Figures 4B, 4C). 322 
While all three cells lines showed differences in overall miR expression profiles, there were 323 
common patterns between the two AT cell lines, which differed from normally responding 324 
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cells (Figure 1A). MiR424-5p presented the most marked differential expression between 325 
2139 and both AT cell lines, with a 3.8-fold decrease in normally responding cells, and a 1.9- 326 
fold increase in ATM-deficient cells (Figure 4B). MiR618 also decreased in normally 327 
responding cells by 2.5-fold relative to the mean, while expression increased in both AT cell 328 
lines (Figure 4B). Conversely, miR335-3p increased in normally responding cells by 3.4- fold, 329 
with a decrease in both AT cells lines by an average of 1.7 fold relative to the mean (Figure 330 
4C).  331 
MicroRNA biomarkers of radiation response 332 
MicroRNA (miR) analysis was performed on the control (2139) and two AT (AT2Bi, AT3Bi) cell 333 
lines, to generate miR expression profiles and elucidate the efficacy of miR as a biomarker of 334 
radiation response, compared to the cytogenetic and DNA damage biomarkers shown in 335 
Figures 1-3. Figure 4A illustrates a heatmap presenting the most highly expressed miR in the 336 
cell profiles, which were then further analysed to determine their increase or decrease in cells 337 
deficient in ATM relative to the mean of all cell lines (Figures 4B, 4C). 338 
While all three cells lines showed differences in overall miR expression profiles, there were 339 
common patterns between the two AT cell lines, which differed from normally responding 340 
cells ATM-expressing 2139 cells (Figure 4A). MiR424-5p presented the most marked 341 
differential expression between 2139 and both AT cell lines, with a 3.8-fold decrease in 342 
normally responding cells, and a 1.9- fold increase in ATM-deficient cells (Figure 4B). MiR618 343 
also decreased in normally responding cells by 2.5-fold relative to the mean, while expression 344 
increased in both AT cell lines (Figure 4B). Conversely, miR335-3p increased in normally 345 
responding cells ATM-expressing cells by 3.4- fold, with a decrease in both AT cells lines by an 346 















Figure 4: microRNA expression profiles for control (2139) and AT (AT2Bi, AT3Bi) cell lines as 356 
analysed by Exiqon, Denmark. (A) An unsupervised heatmap analysis of the 50 most highly 357 
expressed miR in all three cell lines, ranging from green to red to reflect the level of decrease 358 
or increase from the mean. Increased (B) and decreased (C) miR expression in AT cells 359 
relative to the mean of all cell lines. Data shown are representative of one independent 360 
experiment. 361 
 362 
Analysis of differentially expressed microRNA reveals common gene targets. 363 
A panel of targets for the most differentially expressed miR was compiled through a 364 
systematic literature search, with emphasis on genes with roles in DNA damage response and 365 
repair.  ATM is an integral part of this machinery and it was hypothesised that its deficiency 366 
in AT cell lines would be reflected in an increase or decrease in expression of a panel of miR.  367 
The mean expression of miR in all three cell lines (2139, AT2Bi and AT3Bi) was calculated and 368 
each individual cell line subtracted from the mean. MiR that were consistent in expression 369 
between both AT cell lines and different from the control cells were included, with the targets 370 
for those miR also detailed. As shown in Table 2, the predominant DNA repair-associated 371 
genes identified as targets of miR increased or decreased in AT cells included the tumour 372 
suppressor phosphatase and tensin homolog (PTEN) and the G1/S cell cycle checkpoint gene 373 
cyclin D1 (CCND1). These genes were both found to be directly and indirectly regulated by the 374 






Gene biomarkers of radiation response 379 
Gene expression analysis of PTEN and CCND1 was carried out in normal (C1 and 2139) and AT 380 
(AT2Bi and AT3Bi) cell lines.  RT-PCR was performed on cDNA isolated from all cell lines to 381 
investigate the expression of miR target genes exposed to 0, 0.05 and 0.5 Gy IR. Fold increase 382 
of genes was calculated using the 2-ddCt method, relative to 0 Gy controls and an expression 383 
was recorded over a value of 1 (Y-axis). In Figure 5, it is evident that the expression of PTEN 384 
(Figure 5A) and CCDN1 (Figure 5B) was elevated after irradiation to 0.05 Gy relative to 0 Gy in 385 
2139 and AT cells. Normally responding C1 cells showed a modest increase in expression of 386 
both genes in response to irradiation, however the relative increase did not exceed 2.2 fold 387 
(CCND1, 0.5 Gy). The highest increase in PTEN expression was observed in AT3Bi cells, with a 388 
35-fold increase relative to sham-irradiated cells, although this was not significant (Figure 5A). 389 
The largest increase observed in CCND1 expression was seen in 2139 cells, with a 6.4-fold 390 
increase over sham-irradiated cells. The AT cell lines showed a more modest increase of 2.6 391 
(AT2Bi) and 4.7-fold (AT3B) (Figure 5B).  However, due to inter-experimental variation, these 392 
fold changes were not significant. 393 
 394 
Table 2: Expression panel of miR upregulated or downregulated in both AT cell lines 395 
compared to control cells, relative to the mean of all cell lines.  396 
miR Expression in AT 





hsa-miR-135a-5p  FOXO1 (CCND1) [42] 
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hsa-miR-152-3p  PTEN [43] 
hsa-miR-223-3p  FOXO1 (CCND1) [44] 
hsa-miR-328-3p  TCF7L2 (CCND1) [45] 
hsa-miR-424-5p   PTEN [46] 
hsa-miR-618   PI3K/Akt pathway [47] 
hsa-miR-92a-1-5p  PTEN [48] 
hsa-miR-99a-5p  AGO-2 (PTEN) [49] 
hsa-miR-138-5p   CCND1 (PTEN) [50, 51] 
hsa-miR-141-3p  PTEN (CCND1) [52, 53] 
hsa-miR-181d-5p  PTEN [54] 
hsa-miR-335-3p  PTEN [55] 
hsa-miR-497-5p  CCND1 [56] 
 397 
 398 
Figure 5: Expression of miR target genes PTEN and CCND1. (A) PTEN gene expression 399 
upregulated in both AT cells and 2139 compared to C1 LCL at 0.05Gy compared to 0 and 400 
0.5Gy IR. (B) CCDN1 gene expression also upregulated in AT cells and 2139 compared to C1 401 
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at 0.05Gy. old increase of genes was calculated using the 2-ddCt method, relative to sham-402 
irradiated cells. Data shown are representative of 3 independent experiments, mean +/- SD. 403 
DISCUSSION 404 
Many advances have has been made in low dose radiation research throughout this decade 405 
and through the multidisciplinary European Union DoReMi consortium (2010-2015), which 406 
arose from the original recommendations made by the High Level Expert Group (HLEG) on 407 
low dose radiation risk research (29). In particular, it was recognised that there was an urgent 408 
need for biomarkers of low dose radiation exposure, individual susceptibility and the effects 409 
of radiation damage (early and late) which have been since characterised by members of the 410 
consortium (4, 6). The authors of this manuscript were also involved in a part of DoReMi for 411 
investigating the use of Raman Spectroscopy as a novel tool and biomarker of individual 412 
radiation sensitivity. Raman Spectra can be generated from patient samples to produce a 413 
unique low dose IR-induced biochemical profile (57, 58). To validate and consolidate Raman 414 
Spectral analyses, the G2 Chromosomal radiosensitivity assay was used as a cytogenetic 415 
Biomarker of radiosensitivity because it was routinely carried out in our laboratory for 416 
different cohorts of patient lymphocytes and cell llines (35-37). In more recent years, our 417 
group has employed the use of γH2AX as a biomarker of DNA damage and individual 418 
radiosensitivity because it can yield quantitative results through flow cytometry with parallel 419 
qualitative confocal imaging and of which is more time-efficient than cytogenetics. 420 
Furthermore, previous reports show increased γH2AX foci increased with increasing radiation  421 
dose in lymphoblastoid cell lines (59). Herein we applied both cytogenetic and γH2AX 422 
biomarkers to assess the radiation sensitivity of normal (C1 and 2139) and clinically 423 
characteristed AT (AT2Bi and AT3Bi) lymphoblastoid cell lines. Lymphoblastoid cell lines (LCLs) 424 
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are T-lymphocytes immortalised with Epstein-barr virus and they were selected because 425 
parallel studies on whole blood lymphocytes from cohorts of patients were being carried out 426 
at the same time and therefore biomarker studies were limited. Although LCLs are not directly 427 
comparable to responses recorded in whole blood lymphocytes, they were advantageous for 428 
conducting the additional biomarker studies reported within. Similarly, the low doses selected 429 
for the experiments were based on the parallel blood studies that were carried out. It was 430 
surprising that the G2 chromosomal radiosensitivity scores in the AT cell lines were not 431 
significantly elevated compared to the control 2139 cells, although cell cycle checkpoint 432 
efficacy observed by mitotic indices (MI) and the calculated radiation-induced mitotic 433 
inhibition (RIMI) appeared to be superior in the 2139 cells compared to both AT cells. This 434 
would be expected if ATM is functional in the normal 2139 cells as ATM transduces the IR-435 
induced DNA damage signal through a serine/threonine phosphorylation cascade. AT2Bi and 436 
AT3Bi cells were derived from clinically characterised AT patients and cellular features of 437 
radiosensitivity was previously established through the colony forming cell survival and 438 
chromosomal assays in which both AT cell lines showed similar spontaneous chromosomal 439 
aberration rates. However clinical and cellular heterogeneity was reported between the cell 440 
types (30). Given this reported heterogeneity between AT2Bi and AT3Bi, and the unexpected 441 
G2 chromosomal radiosensitivity response between the AT cells and 2139, a further 442 
cytogenetic analysis incorporating G-banding with karyotyping and Fluorescent In-Situ 443 
Hybridisation (FISH) using a dual ATM/TP53 probe set was performed. FISH was included in 444 
the analysis as TP53 is directly signalled by ATM phosphorylation and deletions of TP53 has 445 
been previously recored in 17% of B-cell leucocytic leukaemia (B-CLL) (40). Deletions in ATM 446 
in Ataxia-telangectasia patients have been long associated with malignancies such as 447 
leukameia and lymphomas (38, 39), and in particular older AT patients. Since both AT2Bi and 448 
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AT3Bi were derived from a 36 and 15 year old AT patient respectively, the cytogenetic FISH 449 
analysis of ATM and TP53 was warranted. Two copies each of ATM and TP53 were detected 450 
in the control 2139 and AT cells (AT2Bi and AT3Bi) in the specific cells that were analysed and 451 
therefore no specific deletion was detected. There is well-documented evidence of the 452 
heterogeneity in AT mutation types which lead to defective ATM (60-62),  and a significant 453 
proportion are attributed to missense mutations which would not be detectable at the 454 
cytogenetic level and would require molecular characterisation. However, given the 455 
established presence of both copies of ATM by FISH in all cell lines, knowledge of the mutation 456 
type was not required. However, the G-banding karyotyping analysis led to a surprising 457 
incidental finding in the control 2139 cells. The absence of an X-chromosome was evident and 458 
is characteristic of Turners syndrome. There are conflicting reports of chromosomal 459 
radiosensitivity levels in Turner syndrome cells. In one report, 5 patients with the 45, X 460 
karyotype compared to 9 controls irradiated with X-ray (200 rads) demonstrated 461 
chromosomal aberrations similar to the controls, indicating the X-monosomy does not 462 
influence IR-induced chromosomal aberrations (63). However, another report demonstrated 463 
elevated levels of chromosomal radiosensitivity after 3 Gy IR in two comparative Turners 464 
syndrome variants variants (45 X complement and 46 XX gonadal dysgenesis) that were 465 
compared to age- and sex- matched controls (64). There is limited evidence in the literature 466 
to support either hypothesis. In light of this cytogenetic incidental finding, an additional 467 
control lymphoblastoid cell line (C1) was later incorporated as an additional control to 2139 468 
where possible. 469 
The γH2AX biomarker was utilised to measure the IR-induced DNA damage response in all cell 470 
lines (C1, 2139, AT2Bi and AT3Bi). ATM phosphorylation of the variant histone H2AX on serine 471 
139 (γH2AX) localises as discrete nuclear foci quantifiable by immunoflluorescence of which 472 
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a one to one correlation between radiation-induced DSBs and γH2AX foci can be recorded. 473 
The formation of these foci has been shown to be the recognition step for the  non-474 
homologous end joining (NHEJ) DNA repair pathway (15-17). No significant differences 475 
between the cell lines in γH2AX positivity was observed. A study on 40 human cell lines 476 
representing 8 different syndromes to detect a quantitative correlation of cellular 477 
radiosensitivity with various biomarkers; including γH2AX, reported that the IR-induced 478 
γH2AX foci did not predict moderate radiation sensitivities (65). Similarly, γH2AX foci in T-479 
lymphocytes derived from radiotherapy-treated gynacological cancer patients did not 480 
correlate with late radiotoxicity, however the same authors reported a linear dose reponse 481 
with gamma radiation for whole blood and isolated T-lymphocytes (66). A recent critical 482 
review of the functional assays for individual radiosensitivity determined that γH2AX 483 
immunofluorescence alone was not sufficient to predict radiosensitive cases and that other 484 
cytogenetic biomarkers or cell survival bioassays are too time consuming to predict 485 
radiosensitivity in routine clinical use (67). This  further necessitates the requirement for 486 
further molecular biomarkers. 487 
Given the overall poor correlation of radiosensitivity with the cytogenetic and γH2AX 488 
biomarkers in our lymphoblastoid cell lines, a genetic approach was favoured but with 489 
complementarity to the previous chromosome and DNA damage biomarkers, with a focus on 490 
the ATM/chk2/P53 pathway with other DNA damage and repair mechanisms. A microRNA 491 
(miR) expression panel of 752 miR was performed on the control (2139) and AT (AT2Bi and 492 
AT3Bi) cell lines and a panel of gene targets for the most differentially expressed miR was 493 
compiled, with an emphasis on DNA damage response genes to align with our chromosome 494 
and DNA damage biomarkers related to the ATM/chk2/P53 signalling pathway.  One of the 495 
limitations of this study was the reliance of only one control (2139) cell line, which was due 496 
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to the high cost associated with the microRNA  experiment. Upregulated microRNAs of miR-497 
152-3p (43), miR4-24-5p (46) and miR-92-15p (48) indicated that PTEN (phosphatase and 498 
tensin homolog) was a potential target and all downregulated miR indicated both PTEN and 499 
CCDN1 genes as potential targets. The expression of both PTEN and CCCDN1 genes were 500 
analysed in all cell lines and were shown to be upregulated expressed at the lower IR dose of 501 
0.05 Gy. Interestingly, the C1 control showed no significant expression of PTEN compared to 502 
2139, AT2Bi and AT3Bi, with a dose-dependent expression profile for CCDN1. PTEN  negatively 503 
regulates the PI3-Kinase/Akt pathway and has been associated with radiosensitivity and 504 
impaired double strand break repair in lung and prostate cancer cells (68, 69). Other studies 505 
have reported that PTEN mutations lead to radioreistant phenotypes in glioblastoma (GBM) 506 
(68) with resistance mechanisms mediated by phosphorylation of PTEN on Tyrosine240 507 
(pY240-PTEN,) leading to DNA repair through Rad51 (70). CCDN1 is the regulatory subunit of 508 
cyclin dependent kinases (CDK) which phosphorylates and inactivates retinoblastoma (RB) 509 
protein to promote cell cycle progression in the G1/S stage, and is directly signalled through 510 
the ATM/Chk2/P53 pathway. Both potential biomarkers are related to the DNA damage and 511 
repair mechansisms induced by ionising radiation and warrant further invesitgation and 512 
validation with more radiation doses, cell lines or biological models. 513 
 514 
CONCLUSION 515 
There was an unexpectedly poor correlation orbserved between the control 2139 cell line 516 
with the AT (AT2Bi and AT3Bi) cell lines using cytogenetic and γH2AX biomarkers, most likely 517 
due to the underlying cytogenetic abnormality identified in the control 2139 cells. However, 518 
this is not withstanding the fact that these biomarkers have proved invaluable for other 519 
associated studies carried out at our Institute (35-37, 58). When a genetic approach analysing 520 
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miR and their gene targets was taken, a better comparison could be made between the 521 
control 2139 and AT cells. This miR analysis indicated potential genetic biomarkers of 522 
radiosensitivity as well as providing mechanistic insights into the low dose radiation response 523 
particularly for 0.05 Gy. Although the speed at which molecular work can be conducted with 524 
the provision of additional mechanistic information of radiation response, it is also important 525 
that the traditional more time-consuming methods of cytogenetics and cell survival should 526 
not be overlooked. These assays are nontheless hugely informative and reliable, and they are 527 
supported by decades of work in radiation research and in contrast, molecular technologies 528 
are advancing at a rapid rate with far less validation. When undertaking a molecular study on 529 
radiosensitivity biomarkers, we suggest a multi-biomarker approach to include optimised 530 
traditional  methods with considerations for the biological model, dose-dependance and the 531 
scale of the study. 532 
 533 
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